In terms of the service a research site provides to the sponsor of a study, regulatory work is of utmost importance. Regulatory teams are burdened with figuring out how to make sure this critical work is done even when all the parties involved in the study are not in the same room. This is particularly true during this pandemic. So how do regulatory teams provide the highest quality especially during this time?
Society for Clinical Research Sites (SCRS) sought the answer to that question in a recent episode of the organization’s “SCRS Talks” podcast series when they interviewed Complion CEO Rick Arlow.